Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Literature DB >> 9295178

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

J Staedt¹, F Wassmuth, U Ziemann, G Hajak, E Rüther, G Stoppe.

Abstract

A double-blind randomized crossover study of 0.125 mg Pergolide (Lilly) at bedtime versus 250mg L-Dopa + Carbidopa (Roche) was conducted in 16-day phases in 11 patients with idiopathic restless legs syndrome. Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide. Only 1 patient experienced an improvement of restlessness after L-Dopa. The patients showed polysomnographically a mean decrease in NMS cluster disturbed time by 45% from control on L-Dopa (p < 0.025) and by 79% from control on Pergolide (p < 0.001). In addition, Pergolide increased the total sleep time compared to L-Dopa (p < 0.05). In conclusion, the dopamine agonist Pergolide is superior to L-Dopa in the treatment of RLS and NMS.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1997 PMID： 9295178 DOI： 10.1007/BF01277664

Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575

23 in total

1. Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188

2. Dopaminergic treatment of restless legs and rebound phenomenon.

Authors: C Guilleminault; M Cetel; P Philip
Journal: Neurology Date: 1993-02 Impact factor: 9.910

3. [Apropos of some nocturnal myoclonic manifestations. (Symonds' nocturnal myoclonus)].

Authors: E Lugaresi; G Coccagna; D Gambi; G B Ceroni; M Poppi
Journal: Rev Neurol (Paris) Date: 1966-09 Impact factor: 2.607

4. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

Authors: C Brodeur; J Montplaisir; R Godbout; R Marinier
Journal: Neurology Date: 1988-12 Impact factor: 9.910

5. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

Authors: J Staedt; G Stoppe; A Kögler; D Munz; H Riemann; D Emrich; E Rüther
Journal: J Neural Transm Gen Sect Date: 1993

6. Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists.

Authors: G G Yarbrough; J McGuffin-Clineschmidt; D K Singh; D R Haubrich; R J Bendesky; G E Martin
Journal: Eur J Pharmacol Date: 1984-03-16 Impact factor: 4.432

7. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

Authors: J Staedt; G Stoppe; A Kögler; H Riemann; G Hajak; D L Munz; D Emrich; E Rüther
Journal: J Neural Transm Gen Sect Date: 1995

Review 8. Restless legs syndrome.

Authors: William G Ondo
Journal: Curr Neurol Neurosci Rep Date: 2005-07 Impact factor: 5.081

Review 9. Treatment of restless legs syndrome.

Authors: Cynthia L Comella
Journal: Neurotherapeutics Date: 2014-01 Impact factor: 7.620

Review 10. Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors: Pankaj Satija; William G Ondo
Journal: CNS Drugs Date: 2008 Impact factor: 5.749

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

1. Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

2. Dopaminergic treatment of restless legs and rebound phenomenon.

3. [Apropos of some nocturnal myoclonic manifestations. (Symonds' nocturnal myoclonus)].

4. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

5. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

6. Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists.

7. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

8. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.

9. Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports.

10. Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam.

1. Restless Legs Syndrome.

2. Myoclonus.

Review 3. Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Review 4. Restless legs syndrome: pathophysiology, clinical presentation and management.

Review 5. Management of restless legs syndrome in patients on dialysis.

6. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

7. Restless legs syndrome: pathophysiology and treatment.

Review 8. Restless legs syndrome.

Review 9. Treatment of restless legs syndrome.

Review 10. Restless legs syndrome: pathophysiology, diagnosis and treatment.